Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHN939 in Moderate-to-Severe Active Thyroid Eye Disease (TED)
NCT07720635Phase 3Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 3 trial of KHN939 in thyroid eye disease (TED). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
KHN939
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07720635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720635.